Latest News and Press Releases

Exclusive agreement with Jamjoom Pharma covers commercialization and distribution of QUVIVIQ™ (daridorexant) in Saudi Arabia and the Levant region Allschwil, Switzerland – July 27, 2026Idorsia Ltd...

Idorsia will publish its Half Year 2026 Financial Reporting on Thursday July 30, at 07:00 CEST. An investor webcast and conference call will be held to discuss the results on the same day. Date:...

Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Roland Wandeler as CEO – effective October 1, 2026 – an experienced biopharmaceutical executive combining scientific expertise with...

Allschwil, Switzerland – June 26, 2026Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing...

Ad hoc announcement pursuant to Art. 53 LR Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rateFirst tranche will fully refinance the existing New...

High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides difficile bacteria and spores Allschwil, Switzerland – June 1, 2026Idorsia Ltd...

The findings demonstrate that aprocitentan may help reduce the risk of kidney disease progression, cardiovascular events, and mortality in patients with resistant hypertension. Allschwil, Switzerland...

Allschwil, Switzerland – May 6, 2026At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the...

Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next stepsCo-promotion of QUVIVIQ is...

Allschwil, Switzerland – April 10, 2026Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting...